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Abstract
Background: Preterm birth, small size for gestational age (SGA) and large size for gestational age (LGA) at birth are
major risk factors for neonatal and long-term morbidity and mortality. It is unclear which periods of pregnancy are
optimal for ultrasound screening to identify fetuses at risk of preterm birth, SGA or LGA at birth. We aimed to
examine whether single or combined second and third trimester ultrasound in addition to maternal characteristics
at the start of pregnancy are optimal to detect fetuses at risk for preterm birth, SGA and LGA.
Methods: In a prospective population-based cohort among 7677 pregnant women, we measured second and third
trimester estimated fetal weight (EFW), and uterine artery pulsatility and umbilical artery resistance indices as
placenta flow measures. Screen positive was considered as EFW or placenta flow measure < 10th or > 90th
percentile. Information about maternal age, body mass index, ethnicity, parity, smoking, fetal sex and birth
outcomes was available from questionnaires and medical records. Screening performance was assessed via receiver
operating characteristic (ROC) curves and area under the curve (AUC) along with sensitivity at different false-positive
rates.
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Results: Maternal characteristics only and in combination with second trimester EFW had a moderate performance
for screening for each adverse birth outcome. Screening performance improved by adding third trimester EFW to
the maternal characteristics (AUCs for preterm birth 0.64 (95%CI 0.61 to 0.67); SGA 0.79 (95%CI 0.78 to 0.81); LGA
0.76 (95%CI 0.75; 0.78)). Adding third trimester placenta measures to this model improved only screening for risk of
preterm birth (AUC 0.72 (95%CI 0.66 to 0.77) with sensitivity 37% at specificity 90%) and SGA (AUC 0.83 (95%CI 0.81
to 0.86) with sensitivity 55% at specificity 90%). Combining second and third trimester fetal and placental
ultrasound did not lead to a better performance as compared to using only third trimester results.
Conclusions: Combining single third trimester fetal and placental ultrasound results with maternal characteristics
has the best screening performance for risks of preterm birth, SGA and LGA. As compared to second trimester
screening, third trimester screening may double the detection of fetuses at risk of common adverse birth
outcomes.
Keywords: Fetal growth, Preterm birth, Small size for gestational age, Large size for gestational age, Cohort study,
Screening, Third trimester ultrasound
Background
Preterm birth, small size for gestational age (SGA) and
large size for gestational age (LGA) at birth explain up
to 30% of neonatal death and are strong risk factors for
short-term and long-term morbidity [1, 2]. The majority
of newborns who experience abnormal fetal growth are
unidentified until birth [3–6]. SGA or LGA newborns
who have not been identified antenatally have strongly
increased risks of morbidity and mortality, compared to
those who have been identified antenatally [6–9]. Abnor-
mal fetal growth is an important reason for induction of
labour and is therefore a common cause of induced pre-
term birth [3, 10]. However, studies have shown that
spontaneous preterm birth is often preceded by impaired
or accelerated fetal growth [3, 9]. Current pregnancy
care protocols include dating ultrasounds and detailed
structural ultrasounds at 20 weeks gestational age (GA)
to assess congenital anomalies and fetal size [11, 12].
Third trimester ultrasound screening is mostly used in
selected populations. Technological developments in ob-
stetric ultrasounds may lead to future changes in ultra-
sound screening protocols, such as early-pregnancy size
and congenital anomaly assessment and third trimester
growth assessment. The performance of routine third
trimester ultrasound screening, independent of other
maternal and fetal characteristics, is not clear. A review
of eight controlled trials did not suggest consistent bene-
fits of ultrasound after 24 weeks GA on pregnancy out-
comes [13]. A prospective observational cohort study
among 3977 nulliparous women suggested that third tri-
mester ultrasound, in addition to second trimester ultra-
sound, tripled the detection of fetuses subsequently born
SGA compared to selective third trimester ultrasound
[14].
We used data from a population-based observational
study among 7670 pregnant women to examine whether
single or combined second or third trimester fetal and
placental ultrasound examinations, in addition to mater-
nal characteristics, are optimal to detect fetuses at risk
for preterm birth, SGA and LGA.
Methods
Study design
This study was embedded in the Generation R Study, a
population-based prospective cohort study from early
pregnancy onwards in Rotterdam, the Netherlands [15].
The study has been approved by the local Medical Eth-
ical Committee (MEC 198.782/2001/31). Written con-
sent was obtained from all women. All pregnant women
were enrolled between 2001 and 2005. The response rate
at birth was 61%, which was calculated by dividing the
number of participating live born children by the total
number of live born children born in the study area dur-
ing the inclusion period [16]. A total of 8879 women
were enrolled during pregnancy. We excluded women
without second and third trimester ultrasound data (n =
1130), non-singleton live-births (n = 33), and women
with outcome data missing (n = 46). This led to a popu-
lation for analysis of 7670 pregnant women (Add-
itional file 1, Figure S1 shows the flowchart for the
population for analysis). Additional file 2 contains a
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement for the current study
[17].
Maternal characteristics at the start of pregnancy
We selected maternal characteristics known at the start
of pregnancy, which are important determinants of ad-
verse birth outcomes [3, 18–20]. Maternal age was
assessed at enrolment and categorized; < 25.0 years,
25.0–34.9 years, ≥ 35.0 years [3]. Maternal height (cm)
and weight (kg) were measured without shoes and heavy
clothing at enrolment and BMI (kg/m2) was calculated
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and categorized for clinical purposes: normal weight
(BMI < 25 kg/m2), overweight (BMI 25.0–30.0 kg/m2)
and obese (BMI ≥ 30.0 kg/m2) [19]. Information about
ethnicity and parity and smoking was obtained by ques-
tionnaire and categorized as previously described [3, 18].
Second and third trimester fetal and placental
ultrasounds
Ultrasound examinations were carried out in two dedi-
cated research centres in first (median 13.2 weeks GA,
interquartile range (IQR) 12.2 to 14.7), second (median
20.5 weeks GA, IQR 19.9 to 21.3) and third trimester
(median 30.4 weeks GA, IQR 29.8 to 30.9) [3]. We estab-
lished GA by using data from the first ultrasound [3]. In
second and third trimesters, we measured fetal head cir-
cumference, abdominal circumference (AC) and femur
length to the nearest millimeter using standardized pro-
cedures [21]. Estimated fetal weight (EFW) was calcu-
lated using the formula of Hadlock et al., in line with
clinical practice [22]. GA-adjusted SDS for growth mea-
sures were based on reference growth charts from the
whole study population [3]. In line with clinical practice,
we defined screen-positive as EFW or AC in the lowest
or highest decile in second or third trimester [5, 8, 14,
23, 24]. Both extremes of EFW and AC are associated
with a higher risk of common adverse birth outcomes
and perinatal morbidity and mortality [3, 14]. This ap-
proach leads to one screening test for all adverse birth
outcomes, which strongly improves ease-of-use in clin-
ical practice. However, EFW > 90th percentile is not as-
sociated with an increased risk of delivering a SGA
newborn. Similarly, EFW < 10th percentile is not associ-
ated with an increased risk of delivering a LGA new-
born. Thus, defining screen positive as EFW < 10th
percentile and > 90th percentile for all adverse birth out-
comes in our screening models may reduce the observed
screening performance. The performance of the screen-
ing model may be improved when we define screen posi-
tive separately for SGA (as EFW < 10th percentile) and
for LGA (as EFW > 90th percentile). We consider one
combined screening test for all adverse birth outcomes
more applicable for clinical practice, but to assess
whether this affects the observed screening performance,
we also evaluated screening performance of models in
which we defined “screen-positive” separately for SGA
(EFW < p10) and LGA (EFW > p90). Second-to-third tri-
mester EFW or AC change was classified screen-positive
if the change was in the lowest or highest decile.
Uterine artery resistance indices (UtA-RI) and umbilical
artery pulsatility indices (UA-PI) are measures of vascular
resistance in the uterine and umbilical arteries, respect-
ively. Increased UtA-RI and UA-PI are associated with im-
paired placental vascular development and increased risks
of abnormal intrauterine growth and adverse perinatal
outcomes [23, 25–29]. These parameters may therefore be
of additional value in clinical screening models. These pa-
rameters were derived from flow velocity waveforms in
second and third trimesters [30]. We defined screen-
positive UtA-RI or UA-PI or second-to-third trimester
change as a value in the highest decile.
Birth outcomes
Information about offspring sex, GA and weight at birth,
gestational hypertensive disorders, assisted vaginal deliv-
ery and cesarean delivery was obtained from medical re-
cords [15]. GA-adjusted SDS for birth weight was
constructed using North European growth standards
[31]. Preterm birth was defined as GA < 37 weeks at
birth. Spontaneous preterm birth was defined as spon-
taneous preterm labour or preterm premature rupture of
membranes resulting in birth < 37 weeks’ GA. According
to clinical standards, SGA and LGA at birth were de-
fined as a GA-adjusted birth weight < 10th and > 90th
percentile in the study cohort, respectively.
Statistical analyses
First, we calculated the absolute percentages of screen
positive second and third trimester fetal ultrasounds
among newborns born preterm, SGA and LGA. Second,
we aimed to assess screening performance for preterm
birth, SGA and LGA based on different predefined screen-
ing models. We constructed five predefined logistic re-
gression models for screening of preterm birth, SGA and
LGA, respectively. Preterm birth, SGA and LGA were the
dependent variables in these different predefined logistic
regression models. For each logistic regression model, we
assessed the variance explained of the model. We obtained
predicted values from these regression models and further
assessed model performance via receiver operating charac-
teristic (ROC) curves and calculation of the area under the
curve (AUC), along with the sensitivity at different false-
positive rates (1-specificity). The five predefined logistic
regression models for screening of preterm birth, SGA
and LGA were as follows: (1) maternal characteristics
model including maternal age, BMI, ethnicity, parity and
smoking and fetal sex; (2) second trimester model (model
1 plus screening result based on second trimester EFW);
(3) third trimester model (model 1 plus screening result
based on third trimester EFW); (4) combined second and
third trimester model (model 1 plus screening result based
on second and third trimester EFW); (5) second-to-third
trimester fetal growth model (model 4 plus second-to-
third trimester EFW change). To compare model per-
formance of the different predefined models, we assessed
the change in effect size of the obtained AUCs from the
different models. If the change in effect size was consid-
ered clinically relevant, we used the method by DeLong
et al. for assessing whether the AUCs for two or more
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correlated receiver operating characteristic curves were
statistically significantly different [32]. Positive and nega-
tive predictive values (PPV, NPV) and positive and nega-
tive likelihood ratios (PLR, NLR) at a 10% false-positive
rate (90% specificity) were calculated for our best model.
Third, in a subsample of women with placenta flow mea-
sures available, we assessed the additional screening per-
formance of placenta measures by adding second and
third trimester UA-PI and UtA-RI screening results to the
five models using a similar approach. To test the robust-
ness of our findings, we performed 8 formal sensitivity
analyses. We assessed (1) whether screening performance
for spontaneous preterm birth was similar to screening
performance for any preterm birth, (2) whether using
stricter cut-off values to define screen-positive results im-
proved screening performance (EFW < 5th percentile or
EFW > 95th percentile), (3) whether our models improved
when we used AC instead of EFW, (4) whether using only
UA-PI or UtA-RI screening results leads to comparable
screening performance as using both measurements com-
bined, (6) whether defining “screen-positive” for individual
outcomes separately (screen positive as EFW < 10th per-
centile only for SGA and screen positive as EFW > 90th
percentile only for LGA), instead of defining screen-
positive as either EFW < 10th or EFW > 90th for all ad-
verse birth outcomes, affects screening performance, (7)
whether the screening performance changed when the
outcome SGA was defined as moderate or extreme SGA
(gestational-age-adjusted birth weight < 5th or < 3rd per-
centile, respectively) or defined as moderate or extreme
LGA (gestational-age-adjusted birth weight > 95th or >
97th percentile, respectively), (8) whether performance of
our model was similar for selecting SGA or LGA new-
borns with adverse outcomes (SGA pregnancies compli-
cated by gestational hypertensive disorders and LGA
pregnancies resulting in delivery using assisted vaginal
delivery or cesarean section). Finally, to assess how
maternal characteristics affect our obtained screening
performance of the different screening models, we
assessed the screening performance of second and
third trimester ultrasound without incorporating ma-
ternal characteristics in the models. To deal with
missing values, we added a missing category for each
maternal and fetal characteristic to the models. This
approach resembles clinical practice. Analyses were
performed using the Statistical Package of Social Sci-
ences version 24.0 for Windows (IBM Corp., Armonk,
NY, USA).
Results
Participants characteristics
Table 1 shows that 345 (4.5%) newborns were born pre-
term, 768 (10%) were SGA, and 767 (10%) were LGA at
birth. Additional file 1, Table S1 gives all fetal and
Table 1 Characteristics of mothers and their children (N = 7670)
Characteristics Valuea
Maternal characteristics
Age, median (IQR), years 30.3(25.9 to 33.4)
< 25, no. (%) 1573(20.5)
25–35, no. (%) 4972(64.8)
> 35, no. (%) 1125(14.7)
Height, mean (SD) (cm) 167.3(7.4)
Weight, mean (SD) (kg) 69.3(13.2)
Body mass index1, mean (SD) (kg/m2) 24.8(4.5)
Normal, no. (%) 4709(61.8)
Overweight, no. (%) 1979(26.0)
Obese, no. (%) 932(12.2)
Education, no. higher education (%) 3055(42.9)
Race/ethnicity, no. (%)
Dutch or European, no. (%) 4289(58.2)
Surinamese, no. (%) 655(8.9)
Turkish, no. (%) 673(9.1)
Moroccan, no. (%) 473(6.4)
Cape Verdian or Dutch Antilles, no. (%) 560(7.6)
Parity, no. nulliparous (%) 4308(56.6)
Smoking, no. (%)
None, no. (%) 4967(72.8)
Early pregnancy only, no. (%) 595(8.7)
Continued, no. (%) 1261(18.5)
Birth characteristics
Males, no. (%) 3861(50.3%)
Gestational age, median (IQR), weeks 40.1(39.1 to 41.0)
Birth weight, mean (SD) grams 3423(544)
Preterm birth2, no. (%) 345(4.5)
Spontaneous preterm birth, no. (%) 294(3.0)
Small-size for gestational age3 < 10 birth centile
(<− 1.4SDS), no. (%)
768(10)
Large-size for gestational age3 > 90 birth centile
(> 1.18SDS), no. (%)
767(10)
Cesarean delivery, no. (%) 836(11.9)
Assisted vaginal delivery, no. (%) 964(13.8)
Apgar score below 7 at 5 min, no. (%) 78(1.0)
aValues are observed data and represent means (SD), medians (IQR) or number
of subjects (valid %). Abbreviations: IQR inter quartile range, SD
standard deviation
1Body mass index is defined as normal (BMI < 25), overweight (BMI 25–30),
obese (BMI > 30)
2Preterm birth is defined as birth < 37 weeks of gestational age
3SGA is defined as < 10th percentile of gestational age- and sex-adjusted birth
weight; LGA is defined as > 90th percentile of gestational age- and sex-
adjusted birth weight
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placental characteristics. Non-response analyses showed
that women without placental measurements were more
likely to have a higher BMI and lower educational level
(Additional file 1, Table S2). Of all newborns with a sec-
ond trimester EFW < 10th percentile or > 90th percent-
ile, 91 (5.9%) were born preterm, 214 (13.9%) were born
SGA and 179 (11.7%) were born LGA. Of all newborns
with a third trimester EFW < 10th or > 90th percentile,
110 (7.2%) were born preterm, 335 (21.8%) were born
SGA and 277 (18.1%) were born LGA (Table 2). In uni-
variate logistic regression analyses, all maternal expo-
sures were associated with at least one of the adverse
birth outcomes, whereas EFW was associated with all
three adverse birth outcomes (results available upon
request).
Screening for risks of preterm birth
Figure 1 shows that the maternal characteristics model
had a moderate performance for the detection of pre-
term birth (AUC 0.60 (95% CI 0.57 to 0.63), which did
not improve by adding second trimester EFW (AUC
0.61 (95% CI 0.58 to 0.64)). Screening improved by add-
ing third trimester EFW (AUC 0.64 (95% CI 0.61 to
0.67) to the maternal characteristics model (p value for
AUC comparison to the maternal characteristics model
< 0.01, Additional file 1, Table S3). AUC effect estimates
did not further improve by combining second and third
trimester EFW results or using EFW change. Adding
placenta flow measures to the third trimester EFW
model strongly improved detection of preterm birth
(AUC of 0.72 (95% CI 0.66 to 0.77), p value for model
comparison to the third trimester EFW model < 0.01,
Additional file 1, Table S3). Compared to the second tri-
mester model, the third trimester model with placenta
flow measures nearly doubled detection of fetuses at risk
of preterm birth, as sensitivity increases from 19% for
the second trimester model to 38% for the third trimes-
ter model with placenta flow measures (PLR 3.8; NLR
0.69; PPV 15%; NPV: 97%) at 90% specificity (Fig. 1,
Additional file 1, Table S4).
We observed similar model performances when we
only took spontaneous preterm birth into account
(Additional file 1, Figure S2). Using stricter diagnostic
cut-offs led to similar AUCs and sensitivities (Fig. 1,
Additional file 1, Figure S3). We did not observe dif-
ferences in results when we used AC instead of EFW
(Additional file 1, Figure S4). Overall, combined use
of UtA-RI and UA-PI tended to be better than separ-
ate use (Additional file 1, Figure S5). Additional file 1,
Figure S6 shows that without maternal characteristics,
screening performance of the third trimester model
with placenta flow measures for preterm birth was
considerably lower.
Screening for risks of small size and large size for
gestational age at birth
The maternal characteristics model and second trimester
model had a moderate screening performance for detec-
tion of SGA at birth (AUCs 0.67 (95% CI 0.65 to 0.69) and
0.72 (95% CI 0.70 to 0.74), respectively) (Fig. 2). Compared
to these models, the third trimester model significantly
improved detection (AUC 0.79 (95% CI 0.78 to 0.81) with
a sensitivity of 50% at 90% specificity (p value for AUC
Table 2 Adverse birth outcomes by second and third trimester estimated fetal weight screening results (N = 7670)a
Preterm birth Small size for gestational age at
birth
Large size for gestational age at
birth
Yes No Total Yes No Total Yes No Total
2nd trimester
Estimated fetal weight < 10th percentile
(screen-positive)
41 (5.3%) 726 (94.7%) 767 192 (25.0%) 575 (75.0%) 767 30 (3.9%) 737 (96.1%) 767
Estimated fetal weight 10–90th percentile
(screen negative)
254 (4.1%) 5882 (95.9%) 6136 554 (9.0%) 5582 (91.0%) 6136 588 (9.6%) 5548 (90.4%) 6136
Estimated fetal weight > 90th percentile
(screen-positive)
50 (6.5%) 717 (93.5) 767 22 (2.9%) 745 (97.1%) 767 149 (19.4%) 618 (80.6%) 767
Total 345 7325 7670 768 6902 7670 767 6903 7670
3rd trimester Yes No Total Yes No Total Yes No Total
Estimated fetal weight < 10th percentile
(screen-positive)
75 (9.8%) 692 (90.2%) 767 331 (43.2%) 436 (58%) 767 4 (0.5%) 763 (99.5%) 767
Estimated fetal weight 10–90th percentile
(screen negative)
235 (3.8%) 5901 (96.2%) 6136 433 (7.1%) 5703 (92.9%) 6136 490 (8%) 5646 (92%) 6136
Estimated fetal weight > 90th percentile
(screen-positive)
35 (4.6%) 732 (95.4%) 767 4 (0.5%) 763 (99.5%) 767 273 (35.6%) 494 (64.4%) 767
Total 345 7325 7670 768 6902 7670 767 6903 7670
aValues are absolute numbers (% of total within the corresponding screening category)
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comparison to the maternal characteristics model and sec-
ond trimester model < 0.01, Additional file 1, Table S3).
Compared to the second trimester model, the third tri-
mester model increased detection of fetuses at risk of
SGA by a third, as sensitivity increases from 33% for the
second trimester model to 50% for the third trimester
model at 90% specificity (Fig. 2, Additional file 1, Table
S4). Effect estimates of the AUCs did not further clinically
improve by combining second and third trimester EFW
results or using EFW change. Adding placenta flow mea-
sures to the third trimester model did slightly improve
screening performance for SGA at birth (AUC 0.83 (95%
CI 0.81 to 0.86) p value for AUC comparison to the third
trimester model < 0.01, Fig. 2, Additional file 1, Table S3)
leading to a sensitivity of 55% at 90% specificity (PLR 5.5;
NLR 0.5; PPV 38%; NPV 95%). The third trimester model
had the best screening performance for detecting LGA
with an AUC of 0.76 (95% CI 0.75 to 0.78) and corre-
sponding sensitivity of 43% at 90% specificity (Fig. 3).
Compared to the second trimester model, the third tri-
mester model increased the detection of fetuses at risk of
LGA by a third, as the sensitivity increases from 28% for
the second trimester model to 43% for the third trimester
model (PLR 4.3; NLR 0.63; PPV 32%; NPV 93%) at 90%
specificity (Fig. 3, Additional file 1, Table S4). Adding pla-
centa flow measures to the third trimester model did not
improve LGA screening performance.
Model performance was the same when screen-
positive was defined separately for SGA and LGA, as
when screen-positive was defined as one screening test
for both SGA and LGA (Additional file 1, Figure S7).
When we used stricter diagnostic cut-offs (screen-posi-
tive defined as EFW < 5th or > 95th percentile), the sen-
sitivities for detection of SGA and LGA slightly
decreased (Figs. 2 and 3 respectively, ROCs and AUCs
in Additional file 1, Figure S3). When we used stricter
outcome cut-offs (extreme SGA and LGA defined as
gestational-age-adjusted birth weight < 3rd or > 97th
percentile, and moderate SGA or LGA defined as
gestational-age-adjusted birth weight < 5th or > 95th
percentile, respectively), the model performance slightly
improved as compared to our main analysis (sensitivities,
ROCs and AUCs in Additional file 1, Figure S8 and Fig-
ure S9). When we assessed screening performance for
SGA newborns with pregnancies complicated by gesta-
tional hypertensive disorders and LGA newborns with
pregnancies resulting in assisted vaginal delivery or
cesarean section, we observed similar model perform-
ance as our main analysis (Additional file 1, Figure S10).
We did not observe differences in results when we used
AC instead of EFW (Additional file 1, Figure S4). When
we excluded maternal smoking from the models, results
were similar (findings not shown). Without incorporat-
ing maternal characteristics in the screening models,
Fig. 1 Screening performance for preterm birth
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screening performance of the third trimester model for
SGA and LGA was considerably lower (Additional file 1,
Figure S6).
Discussion
Our results suggest that third trimester ultrasound
examination in addition to maternal characteristics has
the best screening performance for detecting fetuses at
risk for preterm birth, SGA and LGA, compared to sec-
ond trimester ultrasound or combined second and third
trimester ultrasound. Compared to second trimester
ultrasound screening, third trimester ultrasound screen-
ing would nearly double detection of fetuses at risk of
these adverse birth outcomes in a low-risk population.
Interpretation of main findings
Preterm birth, SGA and LGA are strongly related to peri-
natal morbidity and mortality and have long-term conse-
quences for disease risk [2, 4, 33]. Abnormal fetal growth
and impaired placental function are important risk factors
for adverse birth outcomes, with the strongest associations
observed for third trimester fetal and placental measures
[3–5, 29]. Despite these observed associations, the add-
itional clinical value for third trimester screening for fe-
tuses at risk for common adverse birth outcomes remains
unclear. A review of 13 controlled trials showed no
beneficial effects of routinely performed ultrasound after
24 weeks GA on pregnancy outcomes [13]. These trials
were mainly performed in the early 1990s. Recent devel-
opments in ultrasound techniques and treatment proto-
cols, and changes in prevalence of women at risk of
abnormal fetal growth limit the applicability of these re-
sults to current clinical practice. Technological ultrasound
advancements in obstetrics may lead to implementation of
fetal size and anomaly scans in first trimester and fetal
growth assessment later in pregnancy. Further insight into
the optimal period for ultrasound screening for adverse
birth outcomes is therefore urgently needed.
Despite reported associations of suboptimal fetal
growth and impaired placental function with preterm
birth, no previous studies assessed the screening per-
formance of second and third trimester ultrasound for
preterm birth risk [3, 34]. We observed that third tri-
mester fetal and placental ultrasound together with ma-
ternal characteristics had the best screening
performance for preterm birth. We did not find a bene-
fit of second to third trimester EFW change for screen-
ing for preterm birth, although previously published
work from our cohort showed that second to third tri-
mester EFW change was associated with the risk of
preterm birth [3]. In this previous analysis, we only
assessed the association of second to third trimester
Fig. 2 Screening performance for small size for gestational age
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EFW change with the risk of preterm birth and did not
consider second or third trimester fetal size in the ana-
lysis. Contrary, in our current analysis, we assessed the
screening performance for preterm birth of the addition
of second to third trimester EFW change to second and
third trimester fetal size, and observed it did not further
improve screening performance. Thus, it seems that an
association between second to third trimester EFW
change with the risk of preterm birth is present, but
that this does not add to screening performance for
preterm birth when we also consider second and third
trimester fetal size. The additional value of placenta
measures to the screening model may be explained by
the role of placental dysfunction in preterm birth [1].
We observed the strongest screening performance for
using a combination of umbilical and uterine artery re-
sistance indices. However, differences compared to sin-
gle use of either measurement were small. As the
umbilical artery pulsatility indices are technically easier
to measure, this measure might be most appropriate for
use in clinical practice. Overall, in our relatively healthy
low-risk population, the combination of third trimester
fetal and placental ultrasound with maternal characteris-
tics led to a doubling of antenatally identified newborns
at risk for preterm birth compared to second trimester
ultrasound or maternal characteristics only. A limited
number of previous studies explored screening perform-
ance by single and combined second and third trimester
EFW or AC measurements for prediction of SGA or
LGA, taking into account maternal characteristics. A
retrospective study among 3520 women reported a
moderate screening performance for SGA with a sensi-
tivity of 41.8% at 90% specificity using a combination of
maternal factors, first trimester chemistry results and
second trimester EFW and placenta measures [35]. An-
other retrospective cohort study among 1979 women
reported that adding maternal characteristics and third
trimester fetal and placental ultrasound to second tri-
mester ultrasound results improved sensitivity from 51.3
to 69.7% for SGA and from 44.1 to 59.4% for LGA at
90% specificity [36]. A recent cohort study among 3440
pregnancies assessed the screening value of single versus
serial fetal biometry at 28, 32 and 36weeks GA for
SGA and LGA [37]. This study observed that single
fetal biometry at 32 weeks had a higher sensitivity than
longitudinal analysis from more observations projecting
EFW at 40 weeks [37]. In our study, the third trimester
ultrasound was performed at an average of 30 weeks of
gestation, as compared to an average 34 to 36 weeks of
gestation in other studies [37, 38]. Although screening
performance of third trimester ultrasound may improve
when performed later in the third trimester, third
Fig. 3 Screening performance for large size for gestational age
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trimester ultrasound screening around 30weeks’ gesta-
tion is valuable as it offers a larger window for inter-
ventions. In our study, we observed that third trimester
fetal and placental ultrasound together with maternal
characteristics had the best screening performance for
SGA and LGA. Already in our low-risk population, this
approach led to a third increase in detection of fetuses
at risk of SGA or LGA compared to second trimester
ultrasound screening. We did not observe additional
screening benefit for combining second and third tri-
mester ultrasounds or for using AC instead of EFW.
It is well-established that newborns born SGA or
LGA may be both constitutionally or pathologically
small or large for their gestational age [39]. It has
been suggested that newborns who are pathologically
small or large for their gestational age due to abnor-
mal fetal growth have increased risks of morbidity
and mortality, as compared to those newborns who
are constitutionally small or large for their gestational
age [39]. To better distinguish potential pathological
SGA and LGA newborns from constitutional SGA
and LGA newborns, we also assessed the screening
performance of our screening models for moderate
and extreme SGA and LGA, and for SGA and LGA
complicated by pregnancy or delivery complications.
We found that the screening performance was similar.
This suggests our third trimester screening model
may aid in the identification of newborns who are
pathologically small or large for their gestational age.
We did not use customized birth weight centiles for
classification of abnormal size at birth as a method to
distinguish potential pathological SGA and LGA new-
borns from constitutional SGA or LGA newborns, as
previous studies have not shown strong results re-
garding the use of customized charts to identify SGA
or LGA newborns at higher risk of mortality and ad-
verse short-term and long-term outcomes [40, 41]. A
limitation of our cohort is that we do not have exten-
sive information available on neonatal morbidity. Fur-
ther studies are needed to replicate our findings and
to assess whether our screening model identifies SGA
and LGA born newborns at risk of morbidity and
mortality, considering more detailed measures of neo-
natal morbidity.
Overall, we observed slightly lower sensitivities for
screening for SGA and LGA than previous studies,
which could be explained by taking into account mater-
nal characteristics, our relatively healthy low-risk popu-
lation and the earlier timing of third trimester
ultrasound [37, 38]. As maternal characteristics are sim-
ple and cost-effective measurements, easily available
within clinical practice, we specifically aimed to assess
their screening performance for screening of adverse
birth outcomes within low-risk populations and the
subsequent additional screening performance of more
expensive and time-consuming fetal and placental ultra-
sound measurements. We found that in absence of ma-
ternal characteristics, the screening models had an
inferior screening performance compared to when ma-
ternal characteristics were taken into account but the
third trimester fetal and placental ultrasound still had
the best screening performance for adverse birth out-
comes. Thus, our findings underline the importance of
considering maternal characteristics within low-risk pop-
ulations for screening of adverse birth outcomes and the
potential value of third trimester ultrasound.
Our findings suggest that implementation of third
trimester fetal and placental ultrasound, combined
with common maternal characteristics, would nearly
double detection of fetuses at risk for common ad-
verse birth outcomes compared to second trimester
ultrasound and provides further evidence for critical
evaluation of current obstetric care guidelines. Im-
proved detection of fetuses at risk of preterm birth,
SGA and LGA provides the clinician the opportunity
to optimize monitoring and interventions [42]. Moni-
toring could be intensified by additional assessments
of fetal size, cervical length and umbilical artery
waveforms using (Doppler) ultrasound and fetal well-
being using cardiotocography, which might further
improve detection of fetuses at risk of adverse out-
comes whom may benefit from interventions, such as
administering steroids for fetal lung maturation if pre-
term birth is imminent or termination of pregnancy if
signs of placental insufficiency occur. Previous studies
have shown that SGA or LGA newborns who were
identified antenatally have lower risks of morbidity
and mortality, compared to those who were unidenti-
fied antenatally [6–9]. However, it has also been sug-
gested that prenatal diagnosis of abnormal fetal
growth may lead to poorer outcomes due to subse-
quent interventions [43]. Benefits due to identification
of true positives versus harm caused by false positives
and interventions should be evaluated. Future well-
designed randomized controlled trials are needed to
confirm our results and to assess whether the advan-
tages of screening outweigh the potential harm from
parental anxiety and iatrogenic morbidity, in contem-
porary low-risk populations.
Strengths and limitations
We had a prospective data collection from early preg-
nancy onwards and a large sample of 7670 women
with fetal growth measurements available. The non-
response at baseline might have led to selection of a
more healthy population, which might affect the
generalizability of results to high-risk populations. We
also had a relatively small number of cases of adverse
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birth outcomes, which might further indicate a selec-
tion towards a low-risk population. To assess whether
a screening model improved by adding additional ma-
ternal, fetal or placental characteristics, we assessed if
changes in AUC effect estimates of different screening
models were clinically relevant and whether the dif-
ferences in AUCs of two different models were statis-
tically significant. What is considered clinically
relevant may be arbitrary. Based on previous studies
focused on screening for similar adverse birth out-
comes, we considered an approximate 4–5% change
in effect estimate of the AUC as clinically relevant, as
this change is likely associated with a detectable in-
crease in sensitivity [14, 28, 44]. Next, when model com-
parison fulfilled this criterion, we used a statistical test by
DeLong et al. to see if this change was statistically signifi-
cant [32]. This method takes into account two correlated
AUCs, which is necessary as two curves are constructed
based on the same individuals. We included common ma-
ternal characteristics, easily available within all pregnant
women and applicable to low-risk pregnant populations,
within our maternal screening model. Another predictor
for preterm birth, SGA or LGA at birth is occurrence of
either of these outcomes in a previous pregnancy. We did
not use this maternal characteristic for screening in our
models, as women with a previous preterm birth, SGA or
LGA newborn are already considered higher risk pregnant
women and often intensified monitoring and additional
ultrasounds for fetal growth are indicated. Among higher-
risk populations, a different third trimester ultrasound
screening model including other maternal characteristics
may be more applicable or even a separate screening
model for nulliparous and multiparous women may be
needed. Further studies assessing screening performance
for adverse birth outcomes of third trimester fetal and pla-
cental ultrasound, in combination with more maternal
characteristics such as previous pregnancy complications,
among high-risker populations are needed. All ultrasound
measurements were performed according to the study
protocol and blinded with regard to pregnancy out-
comes due to the prospective nature of the study. Ab-
normal research ultrasound results were reported to
healthcare providers and some participants might
have been treated as a consequence of abnormal (re-
search) ultrasound findings, which might have affected
the screening performance. For example, if an abnor-
mal EFW in a research ultrasound was found, this
may have led to induction of labour before 37 weeks
of gestation, which is considered iatrogenic preterm
birth. However, when we restricted our analyses to
spontaneous preterm birth only, we found similar
screening performance. Thus, the performance of our
model screening for preterm birth does not seem to
be driven by iatrogenic preterm birth.
Conclusion
Maternal characteristics together with single third tri-
mester fetal and placental ultrasound has the best
screening performance for preterm birth, and SGA and
LGA at birth, compared to using only second trimester
ultrasound or combined second and third trimester
ultrasound. Compared to second trimester ultrasound
screening, third trimester ultrasound screening would
nearly double detection of fetuses at risk of these com-
mon adverse birth outcomes in low-risk populations.
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